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Background: Low serum 25-hydroxyvitamin D levels (25(OH)D) have been associated with a higher likelihood of
seasonal affective disorder (SAD) and poor mental well-being, yet firm evidence for either remains lacking. Thus,
vitamin D supplementation may alleviate symptoms associated with SAD.
Methods: This study was a randomized, single-centre, double-blind, placebo-controlled trial including healthcare
professionals employed in psychiatric and somatic hospitals. 3345 healthcare professionals were invited to participate,
50 participants were screened, and 34 were able to complete the study. The main inclusion criterion was 8 points or
more on question no. 2 of the Seasonal Pattern Assessment Questionnaire (SPAQ-SAD). During a 3-month period, the
participants received a daily dose of 70 μg vitamin D or placebo. The primary outcome was the sum of the self-reported
questionnaire Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders (SIGH-SAD).
The secondary outcome was World Health Organization-Five Well-Being Index (WHO-5) of the healthcare professionals
during the winter period and the exploratory outcome measures were weight, waist circumference, blood pressure,
absenteeism from work and 25(OH)D.
Results: There were no significant between-group differences in SIGH–SAD sums at 12 weeks (p = 0.7 (CI: − 3.27 to
4.81)). However, there was a significant improvement of primary SIGH-SAD over time from inclusion (autumn-winter) to
the completion of the study (winter-spring) for all participants. The secondary and exploratory outcome measures were
all insignificant between groups.
The sums of the SIGH–SAD at 12 weeks were not significantly different [p = 0.701 (CI: 4.81–3.27)] between the groups.
There was, however, a significant improvement in primary SIGH-SAD sums over time from inclusion (autumn-winter) to
the completion of the study (winter-spring) in both groups. The secondary and explorative outcome measures were
not significantly different between groups.
Conclusions: There were no significant between-group differences in the primary (SIGH-SAD) and secondary (WH0-5)
as well as the exploratory outcome measures (weight, waist circumference, blood pressure, absenteeism from work
and 25(OH)D. Thus, the study failed to demonstrate an effect of vitamin D on SAD symptoms, but our findings may be
limited by confounders. Furthermore, the study was underpowered and did not allow us to assess the ability of vitamin
D to improve mood in those with low 25(OH)D.
Trial registration: (www.clinicaltrials.gov registration number: NCT01462058).
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Seasonal affective disorder (SAD) [1] manifests as a clin-
ical syndrome with symptoms of depression, carbohy-
drate craving, hypersomnia, lethargy and changes in
circadian rhythms. The symptoms recur each winter
and disappear again during spring or early summer.
Women are more affected than men, and the prevalence
at high latitudes ranges from 1 to 10% [2]. It has been
suggested that the seasonality and symptoms of SAD
may be due to low levels of serum 25-hydroxyvitamin D
levels (25(OH)D) [3]. In the brain 1 alpha-hydroxylase
converts 25-hydroxyvitamin D to the active vitamin D
(1,25(OH)D). Further vitamin D receptors (VDR) are
widespread in the human brain. Thus, it is proposed
that vitamin D operates as a neurosteroid and
thought to be involved in the pathogenesis of depres-
sion [3,4].
Ultraviolet B shortwave (UVB) irradiation of the skin
is the most important source of vitamin D. Irradiation
on a summer day between 20–30 minutes on the face
and arms results in the synthesis of 100–250 μg of vita-
min D, which is subsequently activated in the liver to
25-hydroxyvitamin D. Solar UVB content at high lati-
tudes (above 37 N) is minimal between October and
March, and consequently, the synthesis and stores of
vitamin D during winter and early spring are low [5]. In
Denmark, suboptimal 25(OH)D status is common; thus,
the prevalence of vitamin D deficiency among blood do-
nors is 18%, whereas 47% have vitamin D insufficiency
[6]. Normal 25(OH)D vary between 50–160 nmol/L,
whereas values between 25–50 nmol/L are defined as
vitamin D insufficiency, and deficiency is defined as less
than 25 nmol/L. Additionally, 25(OH)D are lower in
persons with darker skin (types III–VI) as assessed by
the Fitzpatrick classification [7,8].
Vitamin D supplementation in relation to well-being
during the winter season has been studied in three
small studies. A positive effect on well-being and
symptoms of depression was demonstrated, when high
doses of vitamin D (≥100 μg D3 daily) were given for
1 to 3 months [9-11]. One large study (n = 441) dem-
onstrated similar significant improvement in Beck De-
pression Inventory (BDI) scores in treatment groups
receiving 70 μg and 140 μg compared to placebo dur-
ing a 1 year period [12]. Other large studies have
failed to demonstrate effects on symptoms of depres-
sion when low dose vitamin D (≤20 μg daily) was
given [13,14].
Indoor work has been hypothesized as a risk factor for
mood difficulties among civil servants in a Danish cross-
sectional study (latitude 55-57N°), a significant risk re-
duction (odds ratio = 0.63) being found in outdoor
workers (>2 hours/day) [15]. Thus, indoor work might
be a significant risk factor for SAD, since indoor work isby far the most prevalent form of work among the total
work force at temperate latitudes [16].
The most efficient and well-documented therapy for
SAD is light therapy (LT) [17]. However, the neurobio-
logical impact and mechanism of LT is not fully under-
stood. SAD was at first believed to be related to
abnormal melatonin metabolism, but later findings did
not support this hypothesis. Thus, LT during two weeks
can reduce subjective sleepiness, but the effect is not as-
sociated with a rise in levels of melatonin in saliva or 25
(OH)D [18]. However, LT can be challenging to apply,
and compliance might be reduced due to lack of time
and social support [19,20]. Tablet treatment can there-
fore be attractive for some SAD patients. Although stud-
ies of brain serotonin function support the hypothesis of
disturbed activity [20], there is still too little evidence to
draw any overall conclusion regarding the use of second
generation antidepressants for SAD [21]. Bases on esti-
mates of high prevalence of vitamin D insufficiency in
the general Danish population and increased mood dif-
ficulties among Danish indoor compared to outdoor
working personnel: vitamin D supplementation might be
a solution. Thus it could be anticipated that a majority
of the participants with known symptoms of SAD would
develop vitamin D insufficiency during wintertime and
thereby benefit from vitamin D supplementation, which
in the above-mentioned winter season studies has shown
positive effect on well-being.
The purpose of this study was to examine whether
vitamin D supplementation would reduce SAD symp-
toms among indoor workers who had experienced win-
ter depressive symptoms in the past. The secondary
objective was to examine correlations between 25(OH)
D, SAD and mental well-being.
Methods
Design
The study was a randomised, single-centre, double-
blind, placebo-controlled trial including healthcare pro-
fessionals employed in psychiatric and somatic hospitals.
The participants were suffering from moderate seasonal-
ity with SAD symptoms [22]. The participants were ran-
domized to either 70 μg vitamin D or placebo for a
period of 12 weeks during the winter period. The dose
of 70 μg vitamin D was chosen in accordance with the
previous study by Jorde et al. [12] in which the lowest
dose of two active drug arms (70 μg or 140 μg) signifi-
cant improved BDI, without significant differences in
side effects as compared to the placebo group.
The setting
Healthcare professionals were recruited from somatic and
psychiatric hospitals in the Region of Southern Denmark.
The study was carried out by The Research Unit,
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the period from October 1 2011 to March 31 2012.
The study population
Healthcare professionals working in one of the above-
mentioned departments were invited to participate in
the study via direct e-mail, flyers and posters. If the in-
vited healthcare professionals wished to participate, in-
formation were sent to them along with the Danish
version of the SAD questionnaire, Seasonal Pattern As-
sessment Questionnaire (SPAQ-SAD) [23]. SPAQ-SAD
is validated in both psychiatric patients and healthy indi-
viduals, and question 2 (The Seasonality Score) in the
Danish version is the most important and best studied
item of SPAQ-SAD. In the Seasonality Score, the indi-
viduals report the effect the changing of the seasons has
on them in six areas (sleep length, social activity, mood,
weight, appetite and energy level) on a scale of 0 to 4,
with 0 being “no change” and 4 being “extremely marked
change” [23]. The test-retest correlation for Seasonality
Score ranges from 0.65 to 0.87, and the Seasonality
Score has a good internal consistency, Cronbach’s alpha =
0.82 [24]. We decided to invite participants for a baseline
visit if they rated 8 or more in question 2 in the SPAQ-
SAD questionnaire. We chose a cut-off at 8 in order to
include enough participants and gain power; thus, we in-
cluded participants with less severe symptoms equivalent
to moderate seasonality with SAD symptoms. Thus we
did not use the recommended definition by Kasper et al.
[22]. Diagnostic interviews were not planned due to the
public health perspective focusing on symptoms of SAD
rather than the full SAD diagnosis. Participants were eli-
gible if they were 18–65 years old and had signed a written
informed consent form. Exclusion criteria were any form
of schizophrenia, bipolar affective disorder, sarcoidosis, tu-
berculosis and pregnancy, or an intake of more than 10 μg
vitamin D per day or allergy to the content of the pills.
Women of childbearing potential were required to use ef-
fective contraception, and a negative human chorionic
gonadotropin (HCG) pregnancy test for each female
participant was also required at baseline. Furthermore,
participants were excluded if they had a baseline
serum 25(OH)D < 10 nmol/L or > 160 nmol/L, serum
calcium > 1.40 nmol/L, serum phosphate < 1.50 nmol/L
(females) or < 1.60 nmol/L (males aged 18–49 years)
and <1.35 nmol/l (males > 49 years), estimated glom-
erular filtration rate (eGFR) < 60 mL/min/1.73 m2 or
serum parathyroid hormone (PTH) > 9.2 pmol/L.
Eligible participants received information on the study
by the research nurse. The study drug was handed out
along with instructions regarding the blood samples after
informed consent was obtained. A consultant psychiatrist
determined whether all inclusion criteria and no exclu-
sion criteria had been met and enrolled the participants.Randomisation and blinding
The tablets were produced by Vimenco, Denmark, and
were identical in size, smell and taste. The participants
were randomised using blocks of four into the interven-
tion group or the control group. The allocation sequence
was computer generated by the Hospital Pharmacy
Funen, Denmark during the labelling procedure and was
concealed for staff and researchers involved in the trial.
Outcome variables
Primary outcome
The primary outcome was the sum of the Danish version
of the validated self-reported questionnaire Structured
Interview Guide for the Hamilton Depression Rating
Scale, Seasonal Affective Disorders (SIGH-SAD) [25].
Secondary outcome and explorative outcome measures
Secondary outcomes were the sum of the Danish version
of the validated self-reported World Health Organization-
Five Well-Being Index (WHO-5) [26]. Weight, waist cir-
cumference, blood pressure, absenteeism from work and
25(OH)D were exploratory outcome measures.
Assessments
The primary outcome was rated at each visit using a 24-
item SIGH-SAD, a scripted version of the Hamilton De-
pression Rating Scale [27] modified to better reflect the
atypical symptomatology of SAD [25]. This version of
the SIGH-SAD consists of the HDRS 17-item scale plus
the first 7 atypical items (i.e. excluding reverse diurnal
variation). The Danish version was translated from
English and back-translated under supervision by Claus
Martiny PhD, Psychiatric Research Unit, Frederiksborg
General Hospital.
Primary, secondary and explorative outcomes were
assessed at baseline and at 12 weeks after baseline. Add-
itionally, skin type and socio-demographic parameters
were recorded at baseline. Known side effects of vitamin
D supplementation, e.g. fatigue, muscle spasm, pain,
nausea and constipation as well as severe and adverse
events were systematically recorded yes or no at baseline
and endpoint. The use of nutritional supplements and
medication including vitamin D was recorded at baseline
and at the 12-week follow-up.
Treatment adherence was assessed by the counting the
amount of tablets that the participants returned at
12 weeks.
Blood samples were collected at baseline and 12 weeks
later. The blood was analysed for C-reactive protein
(CRP), ionised calcium, phosphate, creatinine, eGFR,
PTH and 25(OH)D (to be reported only at the end of
the trial). PTH analyses were performed on Immulite
2000 from Siemens using a 2-sided chemiluminescent
enzyme-labelled immunometric method. 25(OH)D were
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measures the total amount of vitamin D2 and D3.
Statistical analyses
Differences between the intervention and control groups
with regard to demographic and clinical characteristics
at baseline were tested using Fisher’s exact test for cat-
egorical variables and Wilcoxon rank sum test for nu-
merical variables. For each group, the mean SIGH-SAD
level was calculated at baseline and after 12 weeks. The
difference between the two groups with regard to in-
crease of SIGH-SAD sums over time was compared
using the Wilcoxon rank sum test. In addition, differ-
ences between the two groups in each of the secondary
and exploratory outcomes were tested using Wilcoxon
rank sum test. Correlations between 25(OH)D and
SIGH-SAD and WHO-5 were measured using Spearman
correlation coefficients. The analyses were conducted ac-
cording to intention to treat principles.
All analyses were conducted using STATA/IC 11 (Stata-
Corp LP, College Station, Texas, USA).
Power calculation
We expected a mean reduction of 3 points (standard de-
viation (SD) 6) on the SIGH-SAD according to the smal-
lest clinical important difference in the primary outcome
variable, consistent with a clinical effect of 0.5. Assum-
ing an alpha of 0.05 and a power of 0.90, a sample size
of 85 in each group was calculated. However, only 43
were randomised because of exclusion criteria and few
responders. Only 34 completed the study after drop out,
i.e. 20% of the number needed to give meaningful results
according the power calculation. The achieved sample
size reduced the opportunity to measure a difference of
6 on the scale used.
Ethical approval
The study was approved by the Danish Data Protection
Agency, the Ethics Committee for the Region of Southern
Denmark (ID 301115) and the National Board of Health
(Eudract: 2011-002585-20). The complete protocol can be
acquired by contacting the corresponding author.
Results
Participant flow
In total, 3345 healthcare professionals were employed in
the two hospitals during the inclusion period. All the
employees were invited to participate in the study. 50
were screened by the research nurse, and blood samples
were collected during autumn-winter (October, November
and December 2011). Before randomisation, 7 were ex-
cluded due to abnormal blood samples, mainly because of
PTH levels above 9.2 nmol/L. Therefore, 43 participants
were included in the trial. The mean SPAQ score was11.1, and 19 had a SPAQ score below 11. The mean 25
(OH)D in excluded employees was lower (mean =
50.9 nmol/L (SD 25.7) than in the participants who com-
pleted the study (mean = 68.3) nmol/L (SD 25.3)). Of the
43 participants randomised, 22 received 70 μg of active
vitamin D, and 21 received placebo. 34 completed the
study, and data were collected for the primary, secondary
and exploratory outcomes during winter-spring (January,
February, March 2012) (Figure 1).
Drop-out analysis revealed no significant differences
between the two treatment groups with respect to com-
pletion rates. However, the dropout analysis revealed a
selective dropout for participants with low 25(OH)D
(mean = 52.7 nmol/L (SD 17.7)) (p = 0.04).
Demographic data
The demographic and clinical characteristics at baseline
were similar in the two groups (p > 0.05 for all) (Table 1).
The majority of participants were women (vitamin D
group: 100%; placebo group: 90%), with an average age
of 48 (SD = 12) in the vitamin D group and 44 (SD = 9)
in the placebo group. The majority of participants in
both groups had normal 25(OH)D at baseline (Table 1).
At endpoint, 7 participants had an insufficient 25(OH)D
and 3 had a deficient 25(OH)D, all in the control group.
The mean 25(OH)D at 12 weeks was 46.2 (SD = 21.7) in
the control group.
Outcomes
There was no significant between-group difference in
the decrease of the primary outcome SIGH-SAD over
time (intervention group, mean decrease (SD): −6.4
(7.3); control group, mean decrease (SD): −6.8 (9.5); p =
0.7). Baseline values for SIGH-SAD were not signifi-
cantly different between the intervention group (18.7
(SD 9.3)) and the control group (18.6 (SD 8.3)). The
non-significant mean difference in primary outcome was
0.34 in favour of the placebo group. However there was
an improvement in SIGH-SAD from baseline to comple-
tion of the study for both treatment groups (Figure 2).
There were no significant between-group differences
in the secondary outcomes, .i.e. WHO-5 and the ex-
ploratory outcomes weight, waist circumference, blood
pressure and absenteeism (Table 2).
The results according to the second objective revealed
a weakly correlation between 25(OH)D and WHO-5
(Spearman rho = 0.20) but no correlated between 25(OH)
D and SIGH-SAD (Spearman rho = −0.01) at baseline.
One participant in the control group and none in
the intervention group had used nutritional supple-
ments including vitamin D. The results were not af-
fected when correcting for this. The overall treatment
adherence was high (85.9 (SD 10.3)). However, two
participants with normal 25(OH)D at baseline in the
Figure 1 Flow of participants.
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pletion. The rest of the intervention group had signifi-
cantly higher 25(OH)D.
Side effects and adverse events
There were no significant between-group differences in
recorded known side effects (fatigue, muscle spasm,
pain, nausea, constipation) or in the number of other ad-
verse events recorded. None of the other adverse events
were related to vitamin D. Additionally, between-groupTable 1 Demographic and clinical characteristics of participan
Intervention group n = 2
Female, n (%) 16 (100)
Age mean (SD), years 44.2 (11.5)
Smokers, n (%) 5 (31)
PTH mean (SD), nmol/l 6.1 (1.8)
Skin pigmentation mean (SD) 3.0 (1.0)
Absenteeism mean (SD), days 1.5 (2.7)
Waist circumference mean (SD), cm 90.3 (12.7)
Normal 25(OH)D (>50), n (%) 15 (68)
Insufficient 25(OH)D (25–50), n (%) 7 (32)
Deficient 25(OH)D (<25), n (%) 0 (0)differences in serum phosphate and serum calcium were
non-significant.
Discussion
The objective of this study was to investigate whether
employees with indoor work and SAD symptoms would
benefit from vitamin D supplementation during the win-
ter season, i.e. whether vitamin D would alleviate symp-
toms of depression during the winter and early spring.
The study is qualified due to the block randomisation,ts at baseline
2 Control group n = 21 Both groups n = 43
16 (89) 32 (94)
44.4 (10.0) 44.3 (10.6)
3 (17) 8 (24)
5.6 (2.0) 5.9 (1.9)
2.7 (1.1) 2.9 (1.0)
0.6 (1.2) 1.0 (2.0)
82.5 (8.0) 86.1 (11.0)
16 (76) 31 (72)
5 (24) 12 (28)
0 (0) 0 (0)
Figure 2 Depression symptoms on SIGH-SAD.
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wintertime. Additionally, the double-blinded randomised
design is the best suited to demonstrate an effect of the
intervention. Finally, the trial included both psychomet-
ric assessments as well as levels of the active treatment.
However the design did not favour inclusion of partici-
pants with lower 25(OH)D, thus the study did not allow
an investigation of the ability of vitamin D to improve
mood in those with low 25(OH)D at baseline. Thus, the
overall most significant finding in this study was that
vitamin D had no effect on SAD symptoms.
The findings are different from those achieved in pre-
vious small studies [9,10] and a larger Norwegian study
[12]. In the small studies, the inclusion criterion was 25
(OH)D below 40 nmol/L [9,10], and in the NorwegianTable 2 Increase in secondary and explorative outcomes









WHO-5 6.8 (19.8) 13.0 (19.6) 0.42
Weight, kg 0.9 (1.8) 0.6 (1.7) 0.76
Waist circumference, cm −0.3 (2.9) −1.4 (4.4) 0.50
Blood pressure, mmHg
- Systolic 5.0 (13.0) −0.8 (11.1) 0.21
- Diastolic 1.6 (6.7) 0.3 (9.0) 0.55
Absenteeism, days 1.7 (5.9) 2.6 (5.7) 0.99
Mean increase (SD) from baseline to 12 weeks outcome measurement.study [12], mean baseline 25(OH)D was 52.5 nmol/L.
This indicates that vitamin D supplementation might
only be relevant for those with lower 25(OH)D. We
chose a SPAQ-SAD cut-off at 8 in order to include more
participants with SAD symptoms, thus we included par-
ticipants with less severe symptoms than recommended
by Kasper et al. [22]. The lower SPAQ-SAD cut-off
might have influenced the results negatively due to a re-
duced effect on participants with limited symptoms ac-
cording to the low sensitivity in SPAQ-SAD [28]. The
magnitude of this effect is unknown since we did not
have scores from the summer months.
Both weight and waist-circumference among the par-
ticipants were measured since seasonal affective disorder
is related to an increased appetite, which again results in
an increased risk of the metabolic syndrome. We did not
find any improvement in the blood pressure or a positive
effect on weight. These findings are in accordance with
two other trials which showed no effect of vitamin D sup-
plementation on weight loss among obese patients [29].
There were five main limitations of the study [1]. High
PTH was an exclusion criterion for participation. High
PTH is correlated with low 25(OH)D, and seven partici-
pants were excluded for this reason. This limitation was
defined by the legislative authorities because of the risk
of placebo treatment of secondary hyperparathyroidism
[2]. The drop-outs had a significantly lower 25(OH)D,
which reduced the possibility to demonstrate an effect of
the intervention [3]. We did not reach the calculated
sample size. Thus, the results from the study might have
been subject to a type II error. The study was grossly
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nificantly results was unlikely. We had expected more
participants to enter the study; the most prominent fac-
tor for the women was the criterion that anti-conception
be practised, which many could not meet. The smaller
number of participants, especially among young women,
might weaken the generalizability of the study. This
apart, we consider these data as being potentially rele-
vant for other staff categories with indoor work [4]. The
study was carried out using posters and direct e-mails to
the staff at the two hospitals. Thus, we do not know
whether the participants were representative of people
with SAD symptoms [5]. Finally, we included partici-
pants according to their scores on a single question in
the SPAQ-SAD rather than the full definition of SAD,
but all participants except four had abnormal SIGH-
SADs at baseline. Considering this limitation, we did not
find a difference between the vitamin D and placebo
group but a significant decline of SIGH-SAD in both
groups, which could be due to placebo respond. We could
not explain it by the duration of daylight since time from
solstice did not have an impact on SIGH-SAD.
The participants were respondents of announcements:
neither we do not know the prevalence of winter depres-
sion among health care professionals, nor we do not
know whether the participants had more or fewer symp-
toms than those who did not respond, reducing the ex-
ternal validity of the study. Additionally the trial might
only find relevance for those with milder symptoms and
declined by those with more severe symptoms.
The decision to include participants with 25(OH)D be-
tween 10–160 nmol/L was taken not only to study the
relation between low 25(OH)D status and symptoms of
depression but also to test whether a decrease in 25
(OH)D during the winter season could be a risk factor
for depressive symptoms in those who had previously
experienced these symptoms. However, we did not find
the anticipated prevalent low 25(OH)D during the winter-
time in this study, where those participants thereby could
benefit from vitamin D supplementation, which could be
explained by the high mean status at baseline.
The study had a clinical perspective focusing on partici-
pants who had mild to more severe symptoms of SAD.
Unfortunately, we did not add a healthy control group,
which could have had a more public health perspective.
The participants were allowed to use LT, and in the
written information they were informed that LT has
shown a positive effect on SAD. However, only 4 partici-
pants used LT, which might be the explanation of no
confounder effect on any outcome.
The study does not exclude a positive effect of vitamin
D supplementation on SAD, especially in patients with
low 25(OH)D. Further investigation of SAD and vitamin
D supplementation must therefore include participantswith low 25(OH)D. Moreover, studies must be concluded
during the early winter months in order to ensure no in-
fluence of the increased sunlight after the winter solstice.
Conclusion
There were no significant between-group differences in
the primary (SIGH-SAD) and secondary (WH0-5) as
well as the exploratory outcome measures (weight, waist
circumference, blood pressure, absenteeism from work
and 25(OH)D). Thus, the study failed to demonstrate an
effect of vitamin D on SAD symptoms. These finding
may be limited by the fact that the study was underpow-
ered, and the inclusion did not favour participants with
low 25(OH)D at baseline.
Abbreviation
25(OH)D: Serum 25-hydroxyvitamin D level; CRP: C-reactive protein (CRP);
eGFR: Estimated glomerular filtration rate; SAD: Seasonal affective disorder;
HCG: Human chorionic gonadotropine; LT: Light therapy; PTH: Parathyroid
hormone; SIGH-SAD: Structured Interview Guide for the Hamilton Depression
Rating Scale, Seasonal Affective Disorders; SPAQ-SAD: Seasonal Pattern
Assessment Questionnaire; UVB: Ultraviolet B shortwave; WHO5: World Health
Organization-Five Well-Being Index.
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